Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Revenue (2016 - 2025)

United Therapeutics (UTHR) has disclosed Revenue for 17 consecutive years, with $790.2 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 10102.53% to $790.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Dec 2025, up 49.17% year-over-year, with the annual reading at $3.2 billion for FY2025, 10.61% up from the prior year.
  • Revenue hit $790.2 million in Q4 2025 for United Therapeutics, down from $799.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $799.5 million in Q3 2025 to a low of -$7.9 million in Q4 2024.
  • Historically, Revenue has averaged $532.6 million across 5 years, with a median of $511.4 million in 2022.
  • Biggest five-year swings in Revenue: crashed 890.0% in 2024 and later surged 10102.53% in 2025.
  • Year by year, Revenue stood at $415.2 million in 2021, then rose by 18.38% to $491.5 million in 2022, then plummeted by 99.8% to $1.0 million in 2023, then plummeted by 890.0% to -$7.9 million in 2024, then soared by 10102.53% to $790.2 million in 2025.
  • Business Quant data shows Revenue for UTHR at $790.2 million in Q4 2025, $799.5 million in Q3 2025, and $798.6 million in Q2 2025.